Publications by authors named "Jason S Katner"

Claim this Profile
S
Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.
Junliang Hao, James Beck, Xin Zhou, Gregory L Lackner, Richard Johnston, Jason S Katner

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.
Robert F Bruns, Stephen N Mitchell, Keith A Wafford, Alex J Harper, Elaine A Shanks, Jason S Katner

Neuropharmacology· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.
Linda M Rorick-Kehn, Roberto Ciccocioppo, Conrad J Wong, Jeffrey M Witkin, Maria A Martinez-Grau, Jason S Katner

Alcohol Clin Exp Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade.
Matthew J Fell, Jason S Katner, Kurt Rasmussen, Alexander Nikolayev, Ming-Shang Kuo

Front Psychiatry· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
Matthew J Fell, Jeffrey M Witkin, Julie F Falcone, Jason S Katner, Kenneth W Perry

J Pharmacol Exp Ther· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge.
Matthew J Fell, Jason S Katner, Bryan G Johnson, Albert Khilevich, Jeffrey M Schkeryantz

Neuropharmacology· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
Frank P Bymaster, Jason S Katner, David L Nelson, Susan K Hemrick-Luecke, Penny G Threlkeld

Neuropsychopharmacology· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis